1.
2.
An Bras Dermatol
; 99(3): 450-451, 2024.
Article
in English
| MEDLINE
| ID: mdl-38307808
Subject(s)
Antibodies, Monoclonal, Humanized , Antineoplastic Agents, Immunological , Liver Neoplasms , Melanoma , Skin Neoplasms , Humans , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/therapeutic use , Melanoma/drug therapy , Melanoma/pathology , Melanoma/secondary , Skin Neoplasms/drug therapy , Skin Neoplasms/pathology , Liver Neoplasms/secondary , Liver Neoplasms/drug therapy , Antineoplastic Agents, Immunological/adverse effects , Melanoma, Cutaneous Malignant , Male , Rupture, Spontaneous/chemically induced , Female , Fatal Outcome , Middle Aged , Aged
3.
An. bras. dermatol
; An. bras. dermatol;99(3): 450-451, Mar.-Apr. 2024. graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1556884
4.
An. bras. dermatol
; An. bras. dermatol;97(2): 266-268, Mar.-Apr. 2022. graf
Article
in English
|
LILACS-Express
| LILACS
| ID: biblio-1374234
5.
An Bras Dermatol
; 97(2): 266-268, 2022.
Article
in English
| MEDLINE
| ID: mdl-35144829
6.
An. bras. dermatol
; An. bras. dermatol;96(6): 793-795, Nov.-Dec. 2021. graf
Article
in English
| LILACS
| ID: biblio-1355642
7.
An Bras Dermatol
; 96(6): 793-795, 2021.
Article
in English
| MEDLINE
| ID: mdl-34565646